Serono Rebif Interferon Beta-1a Treatment U.S. Launch Expected Mid-2002

Serono expects to launch its interferon beta-1a treatment Rebif in the U.S. by mid-2002 after receiving the results from a head-to-head study comparing the multiple sclerosis biologic with Biogen's Avonex.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet